SG Americas Securities LLC Buys 363,829 Shares of Indivior PLC $INDV

SG Americas Securities LLC grew its stake in shares of Indivior PLC (NASDAQ:INDV) by 752.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 412,197 shares of the company’s stock after acquiring an additional 363,829 shares during the period. SG Americas Securities LLC owned 0.33% of Indivior worth $14,790,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Indivior in the fourth quarter valued at approximately $312,000. GAMMA Investing LLC lifted its holdings in Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the last quarter. Goldentree Asset Management LP acquired a new stake in Indivior during the 3rd quarter worth approximately $42,630,000. CIBC Bancorp USA Inc. bought a new stake in Indivior in the 3rd quarter valued at $312,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Indivior in the 3rd quarter valued at $33,496,000. Institutional investors own 60.33% of the company’s stock.

Insider Activity

In other news, Director Daniel A. Ninivaggi bought 775 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 16,923 shares of the company’s stock, valued at $598,904.97. This represents a 4.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David E. Wheadon purchased 1,771 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $62,675.69. Following the acquisition, the director owned 14,395 shares in the company, valued at $509,439.05. This trade represents a 14.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 5,842 shares of company stock valued at $203,342.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Northland Securities set a $50.00 price objective on Indivior in a research report on Tuesday, January 20th. Morgan Stanley reissued an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Weiss Ratings downgraded shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. HC Wainwright raised their price target on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Indivior has an average rating of “Buy” and a consensus target price of $39.33.

Indivior Stock Performance

NASDAQ:INDV opened at $28.97 on Friday. The stock has a fifty day moving average price of $32.80 and a 200-day moving average price of $31.00. The company has a market cap of $3.62 billion, a price-to-earnings ratio of 17.66 and a beta of 0.83. Indivior PLC has a fifty-two week low of $8.64 and a fifty-two week high of $38.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Friday, February 27th. The company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.17. The company had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. Research analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.